Show Summary Details
Page of

Mild cognitive impairment 

Mild cognitive impairment
Mild cognitive impairment

Pieter Jelle Visser

, Nienke Legdeur

, Mara ten Kate

, and Daniela Bertens

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 May 2022

The concept of mild cognitive impairment (MCI) has been introduced to describe cognitive impairment in non-demented subjects. Subjects with MCI are of major clinical importance because they have an increased risk to develop dementia. MCI is a frequent condition with a prevalence of 10–20% in the elderly population. Alzheimer’s disease is the most common cause, but any somatic, neurological, or psychiatric disorder and drug that influence brain functioning could cause it as well. A clinical assessment can identify several of the underlying causes and biomarkers may also be useful. Treatment is available for some of the underlying causes of MCI. The development of novel biomarkers, such as tau PET, and novel treatments may increase opportunities to diagnose the underlying pathology and give disease-specific treatments in the future.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.